Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 9/20 | 0.44 |
| ▸ | HTR2A | P28223 | 7/20 | 0.44 |
| ▸ | HTR2B | P41595 | 7/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | WEE1 | P30291 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL653307 | 1.00 | HTR3A (0.50) | HTR3AHTR3EHTR3BADRB1HTR3D | |
| SCHEMBL653028 | 1.00 | HTR3A (0.50) | HTR3AHTR3EHTR3BADRB1HTR3D | |
| Hydrochloric Acid SCHEMBL5632698 | 0.98 | HTR3A (0.49) | HTR3AHTR3EHTR3BADRB1HTR3D | |
| Hydrochloric Acid SCHEMBL5632643 | 0.98 | HTR3A (0.49) | HTR3AHTR3EHTR3BADRB1HTR3D | |
| Hydrochloric Acid SCHEMBL5632640 | 0.98 | HTR3A (0.49) | HTR3AHTR3EHTR3BADRB1HTR3D | |
| SCHEMBL4025392 | 0.84 | ADRB1 (0.52) | ADRB1RAD52HTR2CHTR2AHTR2B | |
| SCHEMBL22542020 | 0.84 | ADRB1 (0.52) | ADRB1RAD52HTR2CHTR2AHTR2B | |
| SCHEMBL22542046 | 0.84 | ADRB1 (0.52) | ADRB1RAD52HTR2CHTR2AHTR2B | |
| SCHEMBL20884553 | 0.83 | RAD52 (0.44) | RAD52HTR2CHTR2AHTR2BWEE1 | |
| SCHEMBL20884942 | 0.83 | RAD52 (0.44) | RAD52HTR2CHTR2AHTR2BWEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 320 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | claimed |
| CN-1809545-A | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5HT2c | ARENA PHARM INC (US) | 2006-07-26 | — | — | CN | claimed |
| EP-1644347-A1 | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT sb 2C /sb RECEPTOR ASSOCIATED DISEASES | Arena Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | claimed |
| WO-2005016902-A1 | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | claimed |
| US-20260092134-A1 | Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery | UNIV JOHNS HOPKINS (US) | 2026-04-02 | — | — | US | disclosed |
| US-12527746-B2 | Peptide/particle delivery systems | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4642434-A2 | LIPID COMPOSITIONS ON THE BASIS OF IONIZABLE LIPIDS, USE FOR DELIVERY TO IMMUNE CELLS | Life Technologies Corporation (US) | 2025-11-05 | — | — | EP | disclosed |
| US-12458700-B2 | Amine-containing transfection reagents and methods for making and using same | Life Technologies Corporation (US) | 2025-11-04 | — | — | US | disclosed |
| US-12371522-B2 | Bioreducible poly (beta-amino ester)s for siRNA delivery | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250136737-A1 | MULTICOMPONENT DEGRADABLE CATIONIC POLYMERS | THE JOHNS HOPKINS UNIVERSITY | 2025-05-01 | — | — | US | disclosed |
| US-20240263196-A1 | Lipid Compositions and Methods for Delivery to Immune Cells | Life Technologies Corporation | 2024-08-08 | — | — | US | disclosed |
| US-12049530-B2 | Multicomponent degradable cationic polymers | THE JOHNS HOPKINS UNIVERISTY (US) | 2024-07-30 | — | — | US | disclosed |
| WO-1998009978-A1 | 6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | ABBOTT LABORATORIES (US) | 1998-03-12 | — | — | WO | disclosed |
| WO-1997042206-A1 | 6-O-SUBSTITUTED ERYTHROMYCIN COMPOUNDS AND METHOD FOR MAKING SAME | ABBOTT LABORATORIES (US) | 1997-11-13 | — | — | WO | disclosed |
| US-5668131-A | CONTROLLING HELICOBACTER BACTERIA | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1997-09-16 | — | — | US | disclosed |
| US-4824840-A | ANTIHISTAMINES, NERVOUS SYSTEM CONTROLLERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-04-25 | — | — | US | disclosed |
| US-4734416-A | ANTIHISTAMINES, CENTRAL NERVOUS SYSTEM CONTROLLING ACTION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-03-29 | — | — | US | disclosed |
| US-4302588-A | 5-(3-SUBSTITUTED AMINO)-2-HYDROXY-PROPYLOXY)-8-HYDROXY OR ALKOXY-CARBOSTYRILS, ADRENERGIC BLOCKING AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1981-11-24 | — | — | US | disclosed |
| US-4289883-A | ADRENERGIC BLOCKING AGENTS OF EXCELLENT CARDIOSELECTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1981-09-15 | — | — | US | disclosed |
| US-4210753-A | TREATMENT OF CARDIAC DISORDERS AND CHRONIC LUNG DISEASE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1980-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527746-B2 | Peptide/particle delivery systems | VEGFA, IGF2BP2, MSTN | HTR3A 2147/4885HTR3E 1396/4885HTR3B 1999/4885 |
| US-20250136737-A1 | MULTICOMPONENT DEGRADABLE CATIONIC POLYMERS | PEF1, FIBP, PARN | HTR3A 1018/4885HTR3E 1159/4885HTR3B 1458/4885 |
| US-12458700-B2 | Amine-containing transfection reagents and methods for making and using same | SNRPA, NUDT21, SOAT2 | HTR3A 2204/4885HTR3E 2058/4885HTR3B 1563/4885 |
| US-12371522-B2 | Bioreducible poly (beta-amino ester)s for siRNA delivery | AARS1, SLC43A1, PHAX | HTR3A 4002/4885HTR3E 3145/4885HTR3B 3494/4885 |
| US-12049530-B2 | Multicomponent degradable cationic polymers | PEF1, FIBP, PARN | HTR3A 1018/4885HTR3E 1159/4885HTR3B 1458/4885 |
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | HTR2C, HTR2A, HTR5A | HTR3A 5/4885HTR3E 18/4885HTR3B 10/4885 |
| US-20260092134-A1 | Bioreducible Poly (Beta-Amino Ester)s For siRNA Delivery | SLC43A1, SLC7A5, SLC7A1 | HTR3A 4257/4885HTR3E 3569/4885HTR3B 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.